Financial Summary (All financials)
In millions, except per share items | Oct-30-22 | Oct-31-21 | Oct-25-20 | Oct-27-19 | Oct-28-18 | Oct-29-17 | Oct-30-16 | Oct-25-15 |
Revenues | 25,785.0 | 23,063.0 | 17,202.0 | 14,608.0 | 16,705.0 | 14,698.0 | 10,825.0 | 9,659.0 |
Revenue growth | 11.8% | 34.1% | 17.8% | -12.6% | 13.7% | 35.8% | 12.1% | 6.5% |
Cost of goods sold | 13,792.0 | 12,149.0 | 9,510.0 | 8,222.0 | 9,188.0 | 8,086.0 | 6,314.0 | 5,707.0 |
Gross profit | 11,993.0 | 10,914.0 | 7,692.0 | 6,386.0 | 7,517.0 | 6,612.0 | 4,511.0 | 3,952.0 |
Gross margin | 46.5% | 47.3% | 44.7% | 43.7% | 45.0% | 45.0% | 41.7% | 40.9% |
Selling, general and administrative | | | | | | | | |
Sales and marketing | 703.0 | 609.0 | 526.0 | 521.0 | 521.0 | 457.0 | 429.0 | 428.0 |
Research and development | 2,771.0 | 2,485.0 | 2,234.0 | 2,054.0 | 2,022.0 | 1,781.0 | 1,540.0 | 1,451.0 |
General and administrative | 735.0 | 620.0 | 567.0 | 461.0 | 483.0 | 876.0 | 390.0 | 469.0 |
EBITA | 7,824.0 | 7,095.0 | 4,421.0 | 3,407.0 | 4,690.0 | 4,129.0 | 2,341.0 | 1,879.0 |
EBITA margin | 30.3% | 30.8% | 25.7% | 23.3% | 28.1% | 28.1% | 21.6% | 19.5% |
Amortization of intangibles | 40.0 | 49.0 | 56.0 | 57.0 | 199.0 | 193.0 | 189.0 | 186.0 |
EBIT | 7,784.0 | 7,046.0 | 4,365.0 | 3,350.0 | 4,491.0 | 3,936.0 | 2,152.0 | 1,693.0 |
EBIT margin | 30.2% | 30.6% | 25.4% | 22.9% | 26.9% | 26.8% | 19.9% | 17.5% |
Pre-tax income | 7,599.0 | 6,771.0 | 4,166.0 | 3,269.0 | 4,396.0 | 3,816.0 | 2,013.0 | 1,598.0 |
Income taxes | 1,074.0 | 883.0 | 547.0 | 563.0 | 1,358.0 | 297.0 | 292.0 | 221.0 |
Tax rate | 14.1% | 13.0% | 13.1% | 17.2% | 30.9% | 7.8% | 14.5% | 13.8% |
Net income | 6,525.0 | 5,888.0 | 3,619.0 | 2,706.0 | 3,038.0 | 3,519.0 | 1,721.0 | 1,377.0 |
Net margin | 25.3% | 25.5% | 21.0% | 18.5% | 18.2% | 23.9% | 15.9% | 14.3% |
|
Diluted EPS | $7.44 | $6.41 | $3.92 | $2.86 | $2.96 | $3.25 | $1.54 | $1.12 |
Shares outstanding (diluted) | 877.0 | 919.0 | 923.0 | 945.0 | 1,026.0 | 1,084.0 | 1,116.0 | 1,226.0 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|